Literature DB >> 17509033

Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities.

Femke P Peters1, K K Krishnadath, Agnieszka M Rygiel, Wouter L Curvers, Wilda D Rosmolen, P Fockens, Fiebo J W Ten Kate, Jantine W P M van Baal, Jacques J G H M Bergman.   

Abstract

OBJECTIVES: Malignant transformation of Barrett's mucosa is associated with the accumulation of genetic alterations. Stepwise radical endoscopic resection of the Barrett's segment with early neoplasia is a promising new treatment resulting in complete re-epithelialization of the esophagus with neosquamous epithelium. It is unknown whether radical resection also eradicates genetic abnormalities. The aim of this study was to prospectively evaluate whether genetic abnormalities as found in the Barrett's segment before radical resection are effectively eradicated and absent in the neosquamous epithelium.
METHODS: Nine patients with early neoplasia who successfully underwent radical resection were included. Immunohistochemistry (IHC) was performed to assess p53 protein overexpression. DNA fluorescent in-situ hybridization was (DNA-FISH) performed for evaluation of numerical abnormalities of chromosomes 1 and 9, and losses of p16 and p53. Immunohistochemistry and DNA-FISH were performed on endoscopic resection specimens of the neoplasia and on follow-up biopsies of the neosquamous epithelium.
RESULTS: DNA-FISH and IHC showed alterations in the pretreatment samples of all patients. All showed aneusomy of chromosome 1 and 9. Loss of p16 and p53 were seen in 6 and 8 patients. IHC showed intense p53 nuclear staining in seven patients. Post-treatment biopsies showed neosquamous epithelium with a normal diploid signal count for all DNA-FISH probes and normal IHC stainings in all patients.
CONCLUSIONS: Radical resection of Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities and results in neosquamous epithelium without these genetic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509033     DOI: 10.1111/j.1572-0241.2007.01272.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  MicroRNA-143 and -205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus.

Authors:  Willem A Dijckmeester; Bas P L Wijnhoven; David I Watson; Mary P Leong; Michael Z Michael; George C Mayne; Tim Bright; David Astill; Damian J Hussey
Journal:  J Gastrointest Surg       Date:  2009-02-04       Impact factor: 3.452

2.  Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma.

Authors:  Bashar J Qumseya; Waseem David; Herbert C Wolfsen
Journal:  Clin Endosc       Date:  2013-01-31

3.  Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.

Authors:  Agnieszka M Rygiel; Francesca Milano; Fiebo J Ten Kate; Jacques J G H M Bergman; Kausillia K Krishnadath
Journal:  J Oncol       Date:  2010-06-09       Impact factor: 4.375

4.  Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection.

Authors:  Roos E Pouw; Joep J Gondrie; Carine M Sondermeijer; Fiebo J ten Kate; Thomas M van Gulik; Kausilia K Krishnadath; Paul Fockens; Bas L Weusten; Jacques J Bergman
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

Review 5.  Barrett's oesophagus: an ideal model to study cancer genetics.

Authors:  Massimiliano di Pietro; Rebecca C Fitzgerald
Journal:  Hum Genet       Date:  2009-04-14       Impact factor: 4.132

Review 6.  Treatment of dysplasia in barrett esophagus.

Authors:  Javier Aranda-Hernandez; Maria Cirocco; Norman Marcon
Journal:  Clin Endosc       Date:  2014-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.